Cifras calculadas a partir de notificaciones regulatorias oficiales — .
Datos financieros
ProfessionalIngresos, márgenes, ratio precio/beneficio y más con el plan Professional.
Pregúntale a la máquina
Busca y compara operaciones de iniciados, sociedades y sus estadísticas en lenguaje natural. Tu pregunta se convierte en una consulta sobre los datos disponibles, no en una conversación ni en asesoramiento de inversión.
Solo datos de Corvus Pharmaceuticals, Inc.. Sin búsqueda web. Se excluyen las estadísticas globales de cada iniciado.
Una búsqueda ejecutada consume un crédito, incluso sin resultados. Los errores y las preguntas no compatibles no consumen créditos.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Fuente de información de mercado · Sep 14, 2026
Identidad según la SEC · Sep 14, 2026
Cronología en el mercado · historial completo
115 compras11 ventas— precio de cierrebarra = volumen usd, escala √haz clic en un periodo para filtrar la tabla
| Iniciado | Tipo | Valor · USD | Detalle | |
|---|---|---|---|---|
| CLARK IAN T | AsignaciónD (derivado) | — | SEC |
| Moore David Scott | AsignaciónD (derivado) | — | SEC |
| Moore David Scott | Compra | $250.2K | SEC |
| Grais Linda Shistorial | AsignaciónD (derivado) | — | SEC |
| van den Broek Richard | AsignaciónD (derivado) | — | SEC |
| Thompson Peter Ahistorial | AsignaciónD (derivado) | — | SEC |
| MILLER RICHARD A MDhistorial | Compra | $60.3K | SEC |
| MILLER RICHARD A MDhistorial | Compra | $23.2K | SEC |
| Chan Andrew C. | AsignaciónD (derivado) | — | SEC |
| Thompson Peter Ahistorial | EjercicioD (derivado) | — | SEC |
| Thompson Peter Ahistorial | EjercicioD (derivado) | — | SEC |
| Thompson Peter Ahistorial | EjercicioD (derivado) | — | SEC |
| Thompson Peter Ahistorial | Ejercicio | $31.8K | SEC |
| Thompson Peter Ahistorial | Ejercicio | $24.6K | SEC |
| Thompson Peter Ahistorial | EjercicioD (derivado) | — | SEC |
| Thompson Peter Ahistorial | EjercicioD (derivado) | — | SEC |
| Thompson Peter Ahistorial | Ejercicio | $49.1K | SEC |
| Thompson Peter Ahistorial | Ejercicio | $14.6K | SEC |
| Thompson Peter Ahistorial | Ejercicio | $39K | SEC |
| Thompson Peter Ahistorial | EjercicioD (derivado) | — | SEC |
| Thompson Peter Ahistorial | EjercicioD (derivado) | — | SEC |
| Thompson Peter Ahistorial | Ejercicio | $30K | SEC |
| Thompson Peter Ahistorial | Ejercicio | $450K | SEC |
| Thompson Peter Ahistorial | EjercicioD (derivado) | — | SEC |
| Thompson Peter Ahistorial | Ejercicio | $187.5K | SEC |